The cdrGPT framework uses protein language models to design the CDRH3 region of antibodies targeting gastric cancer. This deep learning approach replaces labor-intensive manual engineering to optimize antigen recognition for CLDN18.2. It streamlines the discovery of therapeutic candidates. Practitioners can now accelerate the development of high-affinity antibodies using generative AI architectures.